首页 / 院系成果 / 成果详情页

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma 期刊论文

编号：

4dfd4416-15d2-4ae6-8be3-75dfd52fa4b1
作者：

Qin, Chao^[1];Cao, Qiang^[1];Li, Pu^[1];Wang, Shangqian^[1];Wang, Jian^[2];Wang, Meilin^[3];Chu, Haiyan^[3];Zhou, Liqun^[4];Li, Xuesong^[4];Ye, Dingwei(叶定伟)^[5]Zhang, Hailiang(张海梁)^[5]Huang, Yiran^[6];Dong, Baijun^[6];Sun, Xiaofeng^[7];Zou, Qing^[8];Cai, Hongzhou^[8];Sun, Lijiang^[9];Zhu, Jian^[10];Liu, Fade^[11];Ji, Junbiao^[11];Cui, Li^[12];Wang, Xiaoxiang^[13];Zhou, Hai^[13];Zhao, Hu^[14];Wu, Bin^[14];Chen, Jianchun^[15];Jiang, Minjun^[15];Zhang, Zhengdong^[3];Shao, Pengfei^[1];Ju, Xiaobing^[1];Yin, Changjun^[1];
语种：

English
期刊：

SCIENTIFIC REPORTS ISSN：2045-2322 2016 年 6 卷 ; FEB 2
收录：
摘要：

The purpose of the present study was to investigate whether genetic variants that influence angiogenesis and sorafenib pharmacokinetics are associated with clinical outcomes and toxic effects in advanced renal cell carcinoma patients treated with this drug. One hundred patients with advanced renal cell carcinoma were enrolled. Forty-two polymorphisms in 15 genes were selected for genotyping and analyzed for associations with progression-free survival, overall survival, and toxic effects. We found that rs1570360 in VEGF and rs2239702 in VEGFR2 were significantly associated with progression-free. Specifically, patients carrying the variant genotypes (AG + AA) of these two polymorphisms both had an unfavorable progression-free. In addition, compared with those with the rs2239702 GG genotype, patients with the AG + AA genotype suffered an unfavorable OS. We found that the VEGF rs2010963 CG + GG genotypes had a significantly increased risk of hand-foot syndrome, and the ABCB1 rs1045642 CT + TT genotypes had an increased risk of high blood pressure. Our results suggest that polymorphisms in VEGF and VEGFR2 are associated with sorafenib clinical outcomes, and polymorphisms in VEGF and ABCB1 are associated with sorafenib-related toxicities. Larger studies are warranted to validate our findings.
推荐引用方式
GB/T 7714：

Qin Chao,Cao Qiang,Li Pu, et al. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma [J].SCIENTIFIC REPORTS,2016,6.
APA：

Qin Chao,Cao Qiang,Li Pu,Wang Shangqian,&Yin Changjun.(2016).The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma .SCIENTIFIC REPORTS,6.
MLA：

Qin Chao, et al. "The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma" .SCIENTIFIC REPORTS 6(2016).

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0